In the Media
Which ASX companies are resurrecting abandoned drugs? Part 3
Apr 18th, 2024
"SPL has developed its proprietary Dendrimer Enhanced Products platform (DEP) to improve the effectiveness and safety of drugs, especially cancer treatments." Read the full article in Stockhead.
Read More
Which ASX companies are resurrecting abandoned drugs? Part 3
Apr 18th, 2024
DEP is based on dendrimers, which are highly branched polymers, to enhance the delivery of cancer treatments and reduce toxic side effects such as neutropenia, nausea, severe diarrhoea and hair loss from chemotherapy agents. Read the full article in The Australian Business Review.
Read More
Breaking new ground via an oncology treatment tech venture
Apr 9th, 2024
Cheryl Maley, CEO of Starpharma (SPL), provides insight into the partnreship with Medicxi, materialising in Petalion Therapeutics in the UK.
Read More
Aussie tech behind new company
Apr 9th, 2024
Starpharma's partnership with Medicxi was featured in Pharma In Focus.
Read More
Australia's Starpharma and UK-based Medicxi create Petalion Therapeutics to develop novel dendrimer-based treatments
Apr 9th, 2024
Read the coverage of Starpharma's partnership with Medicxi in BioSpectrum Asia.
Read More
Starpharma and Medicxi to partner in Petalion Therapeutics, advancing dendrimer-drug cancer treatments
Apr 9th, 2024
"Australian biotech Starpharma Holdings (ASX: SPL) has entered into a strategic partnership with UK life sciences investment firm Medicxi to establish a UK-based company known as Petalion Therapeutics."
Read More